Mode
Text Size
Log in / Sign up

Machine learning models predict macrophage activation syndrome risk in 737 patients with Still's disease.

Machine learning models predict macrophage activation syndrome risk in 737 patients with Still's dis…
Photo by CDC / Unsplash
Key Takeaway
Note that specific clinical features may suggest a probability of MAS in patients with Still's disease.

This multicenter, prospective observational study enrolled 737 patients with Still's disease within the GIRRCS AOSD Study Group and the AIDA Network Still's Disease Registry. The primary objective was to evaluate the occurrence of macrophage activation syndrome (MAS) and poor prognosis using machine learning techniques, including random forest imputation, regression models, and decision trees. The study population consisted of patients with Still's disease, with MAS occurrence and poor prognosis serving as the primary outcomes of interest.

The analysis revealed that 11.4% of the 737 patients were affected by MAS. Additionally, 3% of patients experienced a poor prognosis. Machine learning models identified a specific combination of features—age ≥ 45 years, ferritin ≥ 4,178.10 ng/mL, CRP ≥ 27.15 mg/L, and a systemic score ≥ 7—which was associated with a 34.7% probability of MAS. A similar probability of 33.5% was observed when age was not included in the model.

Safety and tolerability data, including adverse events, discontinuations, and serious adverse events, were not reported in this study. The authors note that while the combination of identified features may suggest a clinician-friendly algorithm for stratifying MAS probability, the observational design precludes definitive causal conclusions. Key limitations regarding generalizability or external validation were not explicitly detailed in the provided data.

The practice relevance of this study lies in its potential to offer a data-driven approach for risk stratification. However, clinicians must interpret these probability estimates with caution, recognizing that the evidence is derived from an observational registry without a control group or randomized intervention. These results should not be used to replace established clinical judgment or diagnostic criteria.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectivesThis study aims to explore the application of machine learning techniques in assessing macrophage activation syndrome (MAS) in Still’s disease.MethodsA multicenter, observational, prospective study was conducted, including patients with Still’s disease enrolled in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) AOSD Study Group and the AutoInflammatory Disease Alliance (AIDA) Network Still’s Disease Registry.ResultsA total of 737 patients (age: 35.5 ± 17.8, male sex: 44.7%) with Still’s disease were assessed; 11.4% were affected by MAS, and 3% had a poor prognosis. First, random forest imputation was applied to the original dataset. Subsequently, a machine-learning-driven assessment was developed to explore MAS occurrence. Collectively, regression models, an exploration decision tree, and a random forest were applied, suggesting the importance of ferritin, age, C-reactive protein (CRP), and systemic score. A logistic regression model accounting for data leakage concerns was then generated using these variables, and missing values were imputed using random forest imputation. This analysis supported the role of the selected variables, which were further combined across different clinical scenarios to estimate the probability of MAS. The highest risk of MAS was estimated for patients simultaneously characterized by age ≥ 45 years, ferritin ≥ 4,178.10 ng/mL, CRP ≥ 27.15 mg/L, and a systemic score ≥ 7, corresponding to a 34.7% probability of MAS, as well as for those characterized by ferritin ≥ 4,178.10 ng/mL, CRP ≥ 27.15 mg/L, and systemic score ≥ 7, corresponding to a 33.5% probability of MAS.ConclusionsA machine-learning-driven prediction of MAS was explored in Still’s disease, highlighting the importance of age of onset, hyperferritinaemia, increased CRP, and multiorgan involvement. A combination of these features may suggest a clinician-friendly algorithm for stratifying the probability of MAS during Still’s disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.